Targeted therapy in relapsed classical hodgkin lymphoma.

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Advanced Hodgkin lymphoma (HL) has high cure rates but ~25% of patients do not respond to or relapse after initial therapy.
• Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is effective for relapsed disease, but cure rates are low after ASCT.
• Malignant Reed-Sternberg (HRS) cells in HL are rare and exist within a complex tumor microenvironment.

Purpose of the Study:

• To review the efficacy of brentuximab vedotin (BV) in patients with refractory or relapsed HL.
• To discuss novel agents targeting HRS cells, signaling pathways, and the tumor microenvironment in HL treatment.

Main Methods:

• Review of recent clinical trials and FDA approvals for novel HL therapies.
• Focus on targeted agents including antibody-drug conjugates and immunotherapies.
• Analysis of mechanisms of action against HRS cells and the tumor microenvironment.

Main Results:

• Brentuximab vedotin (BV) is FDA-approved for primary refractory HL and post-ASCT relapse.
• BV represents a significant therapeutic advance for patients with limited options.
• Ongoing research explores other novel agents targeting HL pathophysiology.

Conclusions:

• Brentuximab vedotin offers a new therapeutic option for advanced Hodgkin lymphoma patients.
• Targeting HRS cells and the tumor microenvironment are promising strategies for HL.
• Further development of novel agents is crucial for improving outcomes in refractory/relapsed HL.